Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

as compared to placebo.[i]

Per the recommendation from an independent Data Monitoring Committee, the CORRECT study was unblinded in late 2011 following a pre-planned interim analysis that determined that the regorafenib arm showed significant improvement in overall survival; patients on the placebo arm were unblinded and offered treatment with regorafenib.

Bayer plans to submit regorafenib for marketing authorization in mCRC in 2012.

In 2011, Bayer and Onyx entered into an agreement under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology.

About the CORRECT Study

The CORRECT study was an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 760 patients with mCRC whose disease had progressed during or within 3 months following last administration of approved standard therapies, which must have included fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab or panitumumab.[i]

Patients who had withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease were also allowed into the study.

Patients were randomized to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Treatment cycles consisted of 160 mg of regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC.[i]

The study was conducted in North America, Europe, China, Japan and Australia.

About Colorectal Cancer

Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or rectum. The majority of cancers occurring in the colon and rectum are adenocarcinomas, which account for more than 90 percent of all large bowel tumors.[ii]

CRC is the third most commonly diagnosed cancer and the third leading cau
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Pharma Major Lupin Limited ... "Biocom" in Russia subject to certain ... pharmaceutical market which recorded RUB 765 billion in sales, placing ... the world in 2014 (IMS Health). For over a decade, ... continue with this trend, projecting Russia ...
(Date:7/2/2015)... -- The report "Silage Inoculants & Enzymes ... & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & Geography ... & Enzymes Market is expected to reach $489.05 Million ... to 2020. Browse 75 market Tables ... P ages and an in-depth TOC on ...
(Date:7/2/2015)... , 2. Juli 2015 BGI gab ... in Hongkong vom American College of Pathologists ... ist das erste klinische Next-Generation-Sequencing Labor, das ... CAP-Zertifkat erhält und somit die höchsten Standards ... bestehenden US FDA - 21 CFR Part ...
Breaking Medicine Technology:Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... Spectros Corporation announced today that 2011 year-to-date sales revenue ... This continues the third year in a row for ... Tissue Oximeter product line was launched in 2008. ... market is embracing the Spectros state-of-the-art broadband VLS tissue ...
... Humira defect lawyers filed a lawsuit against ... drug, Humira, caused a life-threatening disease, leukemia. ... skin condition, psoriasis.  After taking the drug for approximately ... body while on a family vacation," says drug ...
Cached Medicine Technology:Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011 2Perdue Kidd & Vickery Files Lawsuit Against Abbott Laboratories for Inadequate Leukemia and Cancer Warning 2
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new High ... of media attention. In an effort to spread the news, a comprehensive review ... days many people are feeling overwhelmed by stress and fatigue," reports Hendricks. "Many ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. ... been retained to lead a national president recruitment for Regional Care, ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/3/2015)... TX (PRWEB) , ... July 03, 2015 , ... Jennifer ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms ... new facility medical director of our Sienna Plantation facility,” said Executive Medical Director of ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running a promotion ... of celebrities will have the opportunity to get 10% discount on orders that are ... do not have to use coupon codes or remember redemption codes. , There ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... Donna Edwards (D-Md.) for her introduction of the Stop Overdose Stat (S.O.S.) Act ... by Senator Jack Reed (D-R.I.), this Act seeks to decrease drug overdose – ...
Breaking Medicine News(10 mins):Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... Spanish . Barcelona, Spain: The largest study ... and survival after breast cancer has found that women from ... partly explained by more advanced cancer at diagnosis. Although ... with women consulting their doctors at a later stage when ...
... available in Spanish . Barcelona, Spain: ... surviving breast cancer and delaying childbirth, it is important to ... consideration when deciding on treatment, the seventh European Breast Cancer ... Armstrong, from the Department of Medical Oncology, the Christie NHS ...
... pregnant women in Bergen and Oslo will be invited ... The aim is to find out how influenza in ... also study any implications of vaccination during pregnancy. ... of swine influenza spread in Norway. Many young people ...
... ... ... 24, 2010 -- LogMatrix, a provider of log & threat management (SIEM), automated ... leading publication of security-related products and technologies has named their SIEM products ...
... expert says screening is best way to prevent breast cancer ... for breast cancer does not appear to increase overall survival ... survival rates may instead be due to controlling risk factors ... not as good as we hoped years ago," said study ...
... ... Australian start-up, has been selected to showcase its revolutionary service for managing and paying ... ... innovation conference, Finovate, has selected Controlabill to showcase its revolutionary service for managing and ...
Cached Medicine News:Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 2Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 3Health News:Fertility issues in young women with breast cancer must be addressed 2Health News:Influenza in pregnancy -- new Norwegian study 2Health News:LogMatrix Wins Info Security Products Guide “2010 Global Product Excellence Customer Trust Award” 2Health News:LogMatrix Wins Info Security Products Guide “2010 Global Product Excellence Customer Trust Award” 3Health News:Mammograms May Not Boost Survival, Danish Study Suggests 2Health News:Mammograms May Not Boost Survival, Danish Study Suggests 3Health News:Global Financial Innovations Conference Chooses Australian Start Up, Controlabill 2
... designed with Shallow Point Comfort Optimization for ... with its shallow-angled edges act like blades ... tearing the skin. The unique plastic used ... even for patients with arthritis or weak ...
... tenderfoot infant heelstick device uses a highly sharpened ... a gentle arc. The incision produced is carefully ... where most nerve fibers are located, but through ... high quality blood sample with significantly less pain ...
... To sample blood safely, simply and ... safety lancets comprises five versions, offering a ... to meet all your sampling requirements. ,All ... avoid needlestick injuries and prevent cross-infection, and ...
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
Medicine Products: